Skip to content
VC FundPuts its own capital into companiesActive · deal in last 18 monthsLAST VERIFIED Oct 2026 · 9 SOURCES

Invivo Partners

Also known as Invivo Partners, SGEIC, S.A., Invivo Capital, Invivo Ventures

Barcelona early-stage biotech and AI-deeptech VC manager (Invivo Ventures, Invivo Ventures III, Invivo Ventures AI); €2–4M initial tickets, AUM over €150M.

HEADQUARTERS
Barcelona, Spain
FOUNDED
—
AUM
€150M (2025)
OUTSIDE CAPITAL
Yes
TEAM LISTED
8 people

Focus

STAGES
Pre-SeedSeedSeries A
SECTORS
Biotech & Life SciencesArtificial IntelligenceDeep TechHealthTech
ASSET MIX
Venture capital
GEOGRAPHY
EuropeSpain

Overview

Invivo Partners, SGEIC, S.A. is a CNMV-registered manager (no. 144, March 2019) in Barcelona, managed by Luis Pareras, Albert Ferrer and Laura Rodríguez. Its first fund, Invivo Ventures, closed at €60M; Invivo Ventures III (registered November 2023) targets €100M, and Invivo Ventures AI, announced in September 2025, targets €100M for AI-driven science companies. The firm reports 17 portfolio companies, exits of Sanifit (to Vifor) and Versantis (to Genfit), AUM over €150M, and LPs including the EIF, ICO, ICF, IVF, Barcelona City Council and a majority of private investors.

Investment thesis

Biotech companies with strong in vivo proof of concept and first-in-class potential, especially advanced therapies and synthetic biology, and AI-driven deeptech companies (over half in healthcare). Initial investments €2–4M, follow-ons up to €10M per company, from company creation and seed to Series A, in Europe with a focus on Spain.

PORTFOLIO (12)

People

  • Luis Pareras
    Founder & Managing Partner · source
  • Albert Ferrer
    Founder & Partner · source
  • Laura Rodríguez
    Partner · source
  • Josep M. (Pep) Martorell
    Partner · source
  • Borja Ruiz
    Principal · source
  • Oscar Ferrer
    Head of Operations and Control · source
  • Claudio Santos
    Venture Partner · source
  • Michael Tadros
    Venture Partner · source

Links

Frequently asked questions

Invivo Partners is a VC fund based in Barcelona, Spain.

Yes. Invivo Partners invests its own capital in private companies.

Invivo Partners invests at Pre-Seed, Seed and Series A stages in Biotech & Life Sciences, Artificial Intelligence, Deep Tech and HealthTech.

Invivo Partners's stated ticket size is €2M–€4M.

Key people at Invivo Partners include Luis Pareras (Founder & Managing Partner), Albert Ferrer (Founder & Partner), Laura Rodríguez (Partner) and Josep M. (Pep) Martorell (Partner).

Invivo Partners's investments include Sanifit Therapeutics, Versantis, Minoryx Therapeutics, Peptomyc, ARTHEx Biotech, Corteria Pharmaceuticals, Telum Therapeutics and Integra Therapeutics, among others.

The most recent publicly reported investment by Invivo Partners is Telum Therapeutics (Series A (€18M, existing investor)), announced in Jul 2026.

Yes. Invivo Partners manages capital from outside investors.